Synovial sarcoma in children and adolescents

Journal of Pediatric Hematology/Oncology

Volumn 36, Issue 4, 2014, Pages 257-262

  Kerouanton, Anna ^a   Jimenez, Irene ^a   Cellier, Cecile ^b   Laurence, Valerie ^a,b   Helfre, Sylvie ^a   Pannier, Stephanie ^c   Mary, Pierre ^d   Freneaux, Paul ^b   Orbach, Daniel ^a  

^a INSTITUT CURIE   (France)

^b Department of Radiology ^*  (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

adolescent; pediatric; synovial sarcoma

Indexed keywords

AGE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; FUSION GENE; HISTOPATHOLOGY; HUMAN; JOINT RADIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SYNOVIAL SARCOMA; SYT SSX1 GENE; SYT SSX2 GENE; TUMOR VOLUME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; NEOPLASM INVASIVENESS; SARCOMA, SYNOVIAL; TIME FACTORS;

EID: 84899976133     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000154     Document Type: Review

References (35)

1. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004;22:4040-4050.
2. Orbach D, Mc Dowell H, Rey A, et al. Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: experience of the International Society of Pediatric Oncology, Malignant Mesenchymal Tumors (SIOPMMT) Working Group. Pediatr Blood Cancer. 2011;57: 1130-1136.
3. Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101:627-634.
4. Speth BM, Krieg AH, Kaelin A, et al. Synovial sarcoma in patients under 20 years of age: a multicenter study with a minimum follow-up of 10 years. J Child Orthop. 2011;5: 335-342.
5. Ferrari A, Casanova M. New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther. 2005;5:307-318.
6. Brennan B, Stevens M, Kelsey A, et al. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatr. 2010;55:85-90.
7. Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol. 2003;21:1602-1611.
8. Lagarde P, Przybyl J, Brulard C, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013;31:608-615.
9. Sultan I, Rodriguez-Galindo C, Saab R, et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115:3537-3547.
10. Ferrari A, Miceli R, Casanova M, et al. Adult-type soft tissue sarcomas in paediatric age: a nomogram-based prognostic comparison with adult sarcoma. Eur J Cancer. 2007;43: 2691-2697.
11. Kransdorf MJ, Jelinek JS, Moser RP Jr, et al. Soft-tissue masses: diagnosis using MR imaging. Am J Roentgenol. 1989;153:541-547.
12. Ferrari A, De Salvo GL, Oberlin O, et al. Synovial sarcoma in children and adolescents: a critical reappraisal of staging investigations in relation to the rate of metastatic involvement at diagnosis. Eur J Cancer. 2012;2012:7.
13. Berquist TH, Ehman RL, King BF, et al. Value of MR imaging in differentiating benign from malignant soft-tissue masses: study of 95 lesions. Am J Roentgenol. 1990;155: 1251-1255.
14. Murphey MD, Gibson MS, Jennings BT, et al. From the archives of the AFIP: imaging of synovial sarcoma with radiologic-pathologic correlation. Radiographics. 2006;26: 1543-1565.
15. Hirsch RJ, Yousem DM, Loevner LA, et al. Synovial sarcomas of the head and neck: MR findings. Am J Roentgenol. 1997;169:1185-1188.
16. Van der Woude HJ, Vanderschueren G. Ultrasound in musculoskeletal tumors with emphasis on its role in tumor follow-up. Radiol Clin North Am. 1999;37:753-766.
17. Jones BC, Sundaram M, Kransdorf MJ. Synovial sarcoma: MR imaging findings in 34 patients. Am J Roentgenol. 1993; 161:827-830.
18. van Rijswijk CS, Hogendoorn PC, Taminiau AH, et al. Synovial sarcoma: dynamic contrast-enhanced MR imaging features. Skeletal Radiol. 2001;30:25-30.
19. Charest M, Hickeson M, Lisbona R, et al. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging. 2009;36:1944-1951.
20. Ferrari A, Miceli R, Rey A, et al. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J cancer. 2011;47:724-731.
21. Skapek SX, Chui CH. Cytogenetics and the biologic basis of sarcomas. Curr Opin Oncol. 2000;12:315-322.
22. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYTSSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135-140.
23. Ren T, Lu Q, Guo W, et al. The clinical implication of SS18-SSX fusion gene in synovial sarcoma. Br J Cancer. 2013;109:2279-2285.
24. Wittekind C, Compton CC, Greene FL, et al. TNM residual tumor classification revisited. Cancer. 2002;94:2511-2516.
25. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988; 61:209-220.
26. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27:3126-3132.
27. Stanelle EJ, Christison-Lagay ER, Healey JH, et al. Pediatric and adolescent synovial sarcoma: multivariate analysis of prognostic factors and survival outcomes. Ann Surg Oncol. 2013;20:73-79.
28. Ferrari A, Bleyer A. Participation of adolescents with cancer in clinical trials. Cancer Treat Rev. 2007;33:603-608.
29. Ferrari A, De Salvo GL, Dall'Igna P, et al. Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. Eur J Cancer. 2012;48:3448-3455.
30. Ferrari A, Bisogno G, Alaggio R, et al. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer. 2008;44:1202-1209.
31. Brecht IB, Ferrari A, Int-Veen C, et al. Grossly-resected synovial sarcoma treated by the German and Italian Pediatric Soft Tissue Sarcoma Cooperative Groups: discussion on the role of adjuvant therapies. Pediatr Blood Cancer. 2006;46:11-17.
32. Andrassy RJ, Corpron CA, Hays D, et al. Extremity sarcomas: an analysis of prognostic factors from the Intergroup Rhabdomyosarcoma Study III. J Pediatr Surg. 1996;31:191-196.
33. Italiano A, Penel N, Robin YM, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol. 2009;20:425-430.
34. Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246: 105-113.
35. Krieg AH, Hefti F, Speth BM, et al. Synovial sarcomas usually metastasize after>5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Ann Oncol. 2011;22:458-467.